PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically
significant difference in overall survival (OS) in patients with first-line metastatic colorectal …

Background The microsatellite instability-high (MSI-H) phenotype, present in 15% of early
colorectal cancer (CRC), confers good prognosis. MSI-H metastatic CRC is rare and its …

Microsatellite instability (MSI) is caused by defective mismatch repair in 15–20% of
colorectal cancers (CRCs). Higher mutation loads in tumors with mismatch repair deficiency …

3071 Background: Mismatch repair deficient cancers harbor high levels of microsatellite
instability and somatic mutations. Treatment with anti-PD-1 antibodies has resulted in …

673 Background: Blockade of the PD-L1/PD-1 axis is a proven immunologic approach for
treatment of many cancers; however, not all pts respond to monotherapy. Bev, an anti–VEGF …

3514 Background: Pembrolizumab is approved for the treatment of adult and pediatric
patients (pts) with previously treated MSI-H cancer regardless of tumor type or site. This …

Background: Microsatellite Instability (MSI) status is a good prognostic factor for colorectal
cancer (CRC) but its predictive value for chemosensitivity remains controversial. A previous …

Several forms of genomic instability are known to drive the development of colorectal cancer
(CRC). Chromosomal instability is the most common type found in 85% of the CRC, while …

Colorectal cancers (CRCs) with high microsatellite instability (MSI-H) and deficient mismatch
repair (dMMR) show molecular and clinicopathological characteristics that differ from those …

Background: A recent clinical trial on the immune check-point inhibitor pembrolizumab
demonstrated that microsatellite instability (MSI) is a good biomarker for response to this …